The stock of AlloVir Inc. (NASDAQ:ALVR) increased by $0.09 on Tuesday to finish at $2.24, up 4.19 percent. The last five days have seen an average of 1,866,120 shares of common stock traded. 11 times new highs were reached in the current year, with a fall of -$2.89. The average number of shares traded over the last 20 days was 905,090, while the average volume over the last 50 days totaled 806,748.
ALVR stock dropped -21.13% since last month. On 09/19/23, the company’s shares reached a one-month low of $1.90. The stock touched a high of $10.29 on 02/23/23, after rallying from a low of $2.10 in 52 weeks. The price of ALVR stock has declined by -56.34% or -$2.89 this year, reaching a new high 11 times. Still, the stock price is down -78.23% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ALVR stock investors should be aware that AlloVir Inc. (ALVR) stock had its last reported insider trading activity 33 days ago on Aug 18. On Aug 18, Chief Executive Officer Brainard Diana sold 4,055 shares at $2.79 each. This transaction resulted in the insider making $11,313. On Aug 17, Brainard Diana sold 11,361 shares at a price of US$2.50. After the transaction, the insider now owns 895,938 shares. Sinha Vikas had earlier sold 10,516 shares on Aug 17 for $2.50 a share. The transaction was completed for $26,243.
Financial Health
For the three months ended June 29, AlloVir Inc.’s quick ratio was 8.30, while its current ratio was 8.30, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $171.2 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ALVR’s return on assets (ROA) during the last 12 months has been -60.70%. In the meantime, the return on equity (ROE) for the last 12 months was -74.00%.
Earnings Surprise
According to AlloVir Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that AlloVir Inc.’s quarterly earnings would be -$0.48, but it ended up being -$0.45, beating the consensus by -6.70%. EBITDA was -$47.22 million for the quarter. At the end of AlloVir Inc.’s most recent quarter ended June 29, its liabilities totaled 53.58 million, while its total debt was $31.5 million. Equity owned by shareholders amounts to $113.87 million.
Technical Picture
Here’s a quick look at AlloVir Inc.’s (ALVR) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 31.86%, suggesting the stock is Neutral, with a 106.91% historical volatility rate.
The stochastic %K and %D were 10.89% and 11.46% respectively, while the average true range (ATR) was 0.28. Based on the 14-day stochastic reading of 21.94%, the RSI (14) reading is 35.62%. On the 9-day MACD Oscillator, the stock is at -0.29, and the 14-day reading is at -0.49.
Analyst Ratings
In its analyst report released on August 18, 2023, BofA Securities began covering AlloVir Inc. (NASDAQ: ALVR). The stock was rated as a Buy by the brokerage firm. Analysts have assigned AlloVir Inc. (ALVR) an Buy rating. ALVR is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is ALVR’s price target for the next 12 months?
The current consensus forecast for the stock is between $15.00 and $27.00, with a median target price of $18.50. In analyzing these forecasts, the average price target given by analysts for AlloVir Inc. (ALVR) is $19.75.
